If you wish to continue to this external website, click Proceed. without the spin-off) from 2022, following anticipated lower growth in 2021 due to currency weaknesses and . Cowen's 43rd Annual Health Care Conference With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer > Add the event to my calendar The Consumer Healthcare business comprises major brands targeting oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements. Is this happening to you frequently? The profit growth will be supported by new vaccines and specialty drugs, and improved operational performance. In the EU, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually. In the last five years, through the Biotechnology and Biological Sciences Research Council and Medical Research Council, 13% (450m) of all UK funding has gone to universities in Scotland. No communication and no information in respect of the dividend distribution of the shares of EUROAPI (the Shares) may be sent to the public in any jurisdiction where a registration or approval is required. (Photo by Ben STANSALL / AFP) (Photo by BEN STANSALL/AFP via Getty Images). There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. Unveiling his strategy after joining the drugmaker from Novartis AG in 2019, Hudson said Sanofi's focus would be on vaccines, research and development and Dupixent a psoriasis medicine that the CEO projects will exceed annual peak sales of 10 billion while exiting traditional areas of expertise like cardiovascular and diabetes research. This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. Sanofi's fourth quarter saw consumer health sales rise 5.6%, driven . I am not receiving compensation for it (other than from Seeking Alpha). Bad Vilbel, Germany. Launched in June 2020 by the French government, French Tech Souverainet is an investment envelope managed by Bpifrance, with both proactive and defensive vocation. Other commercial successes in J&Js pharma portfolio include inflammatory disease therapy Stelara, which reaped $7.7bn in revenue last year; monoclonal antibody Darzalex for the treatment multiple myeloma; lymphoma and chronic graft-versus-host disease drug Imbruvica, developed with AbbVie; and antibody-based plaque psoriasis treatment Tremfya. In November 2021, Johnson & Johnson announced it would also split off its consumer . The separation is expected to complete by mid-2022E. Elsewhere, Sanofi said it expects trials of the COVID-19 shot being developed in conjunction with GSK to read out later this quarter, while a late-stage vaccine for respiratory syncytial virus developed with British COVID-19 vaccine-maker AstraZeneca PLC is expected to be filed with regulators this year. It followed a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. "As discussed during our Capital Markets Day in February, simplifying the CHC product portfolio is an important part of our strategy to focus our resources and efforts where we can bring the most value, especially to consumers. The company has also claimed that some of its major shareholders support the spin-off deal. Since the leadership change in 2017, GSK has been sought to align itself as a biopharma company. The prescription and pharmaceutical products that make up much of the new J&J company span several therapeutic areas, and include cancer drugs, vaccines and heart medicines. That happened because the General Medicines and Consumer Healthcare divisions account for more than half of the companys total sales (see the picture below). Please contact the Global Headquarters in France . Active Pharmaceutical Ingredients (APIs) are the chemical or biological substances in a medicine that have a therapeutic effect. French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase Forward-looking statements are statements that are not historical facts. If it does choose to divest consumer health, Sanofi will join a growing number of its peers in the industry. Final note: I am long Sanofi directly through its shares listed in Europe. All in all, considering both the current stock price and the possible catalysts to unlock the intrinsic value of the company, Sanofi is a buy. This acquisition further strengthens STADA as a top-five player in Europes consumer healthcare market, supports our growth acceleration, and is another proof point of STADA as a go-to-partner, commented STADAs CEO, Peter Goldschmidt. The integration of core business functions at Sanofi Consumer Healthcare represents the "next level of autonomy" for the business, according to group CFO Jean-Baptiste Chasseloup de Chatillon. All rights reserved. I am encouraged by the organizations early achievements in our efficiency initiatives, which will allow us to further drive innovation in our business., 1985 - 2023 BioSpace.com. In addition, GSK is continuing with the restructuring and active portfolio management of its consumer-health division ahead of the spin-off, expected by late 2022. "We don't worry about what the other companies do, we worry about what we're doing and we're pleased with what's going on in our consumer business.". Precision medicine has the potential to radically change the way health services are delivered, combining medical expertise with the latest technology to provide bespoke treatments for individual patients. However, if the consumer division no longer holds the deep pockets of the combined company, the risk of future consumer product litigation such as the large talc settlement may decrease.. Physical and Mental Wellness. And Scottish universities have a track record of securing UK funding. As part of Sanofi's ongoing efforts to reduce the complexity of its Consumer Healthcare portfolio and accelerate its growth trajectory, the company has signed an agreement with STADA for the divestiture of 16 Consumer Healthcare products commercialized in Europe. Josephine Fubara Builds strategic relationships, both internally . With Paul Hudson, Chief Executive Officer "We've already doubled the value of that pipeline in just 24 months, but it must continue. I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. For medical information: medinfo.india@sanofi.com , customercare. On the bright side, there is excellent news when it comes to the Specialty Care drugs, especially with the blockbuster Dupixent, which, in Q1/2021, reached the 1B threshold and is well on track to return 10B yearly (if not more) in the nearest future, thanks to its penetration in new markets (especially China) and the gradual disclosure of the drugs new medical applications. Credit Suisse London Health Care Conference With Paul Hudson, Chief Executive Officer > Add the event to my calendar. | As part of its quest to streamline consumer healthcareand eventually spin off the unit as a standalone businessSanofi will offload 16 consumer health products to Germany's Stada . An IPO could come as soon as 2022. Consumer Health (OTC) Products; U.S. My holding period is ideally "forever", even though I can't exclude to make some changes from time to time. Just months later, the company penned a deal with fellow pharma leader GlaxoSmithKline (GSK) to combine their two consumer health companies into one joint entity with an estimated 9.8bn in annual sales. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Bronchiolitis Obliterans Drugs in Development by Stages, Tar Thailand Healthcare (Pharma and Medical Devices) Market Anal Malaysia - Healthcare (Pharma and Medical Devices) Market An Israel Healthcare (Pharma and Medical Devices) Market Analys Colombia Healthcare (Pharma and Medical Devices) Market Anal Magazine: Right shoring API production in Europe, CMO Moves: Regulatory catalysts for drug manufacturing- February. The Board of Sanofi (ENXTPA:SAN) completed the spin-off 58% stake in EuroAPI on May 6, 2022. Business is on track to demerge and list as a new company in mid-2022. commercializing best-seller drugs. Health. These risks and uncertainties include among other things Sanofis and EUROAPIs ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 and recent armed conflicts will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. As previously announced, under the terms of the transaction, Pfizer owns a 32% equity stake in the joint venture and GSK owns 68%. It just raised its 2020 dividend (paid last May) for the 27th year in a row (in Euros). This is the reason why earnings grew by 5.2% YoY in Q1, despite the reported top-line slowdown. Nicolas Obrist|+ 33 6 77 21 27 55 |nicolas.obrist@sanofi.com, Investor Relations However, net sales took a dive in Q1, declining by roughly 4.6% YoY (reported). The yield is over 3.5% at the current prices. I have developed a broad set . > Add the event to my calendar, An in-depth look at our vaccines business, strategy and roadmap through to 2025/2030, We chase the miracles of science to improve peoples lives and to transform the practice of medicine, Please contact the Global Headquarters in France : This situation is changing rapidly and additional impacts may arise of which we are not currently aware and may exacerbate other previously identified risks. It is provided for information only. Darcy Jimenez is a healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering drug research, development, production and regulation. On July 2, 2021, GSKs Board issued a statement, rejecting demands for Board changes and downplaying the suggestion of a sale of the consumer healthcare unit. With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer Is the microbiome therapy hype up for a reckoning? Morningstar analyst Damien Conover said: The firms timing is surprising, as we dont see any major catalyst for the move. Sanofi India (NSE:SANOFI) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more. As an independent stand-alone company, EUROAPI will be able to fully unlock its growth potential, offering the best alignment of strategy, value creation and financial objectives for all of Sanofis shareholders. Sanofi's CDMO spinoff set for next month as new group targets 2022 revenues of 1B. "It's very significant, we are really reallocating our cost base towards innovation on science," the CFO said. The consumer arm comprised of million- and billion-dollar brands and offering products such as mouthwash, shampoo, and skincare will form a new publicly traded company in the next 18 to 24 months. The rationale is that the company, whose innovation engine has been strongly reliant on its relationship with Regeneron Pharmaceuticals, would be able to invest the proceeds into more internal research. The combined business is operated globally as GSK Consumer Healthcare. Through this transaction, Sanofi is giving its shareholders the opportunity to take part in the success of a leading player in the API market with strong ambitions to become a global champion on a growing and dynamic market, and due to be listed on the regulated market of Euronext Paris. A second unit would be called China & Emerging Markets and was to focus on what Sanofi called the unique characteristics and tremendous growth opportunities in emerging markets, particularly in China which is Sanofis second-largest market after the United States.. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. . Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. All in all, even though the stagnant divisions are at the moment predominant, that story is changing. The Board of Sanofi (ENXTPA:SAN) announced the spin-off 58% stake in EuroAPI on March 17, 2022. We offer a broad range of digestive solutions that work on relieving heartburn, improving liver performance and indigestion and managing diarrhea and constipation. Please. Post separation, the new Consumer Healthcare company is expected be listed on London Stock Exchange (LSE) with ADR to be listed in the US. We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve peoples lives. Sanofi, which has been carving out its consumer group into a separate business since 2019, remains wedded to the unit after a restructuring helped it return to growth last year. I have no business relationship with any company whose stock is mentioned in this article. Home . The New Co. (Consumer Healthcare) will have a portfolio of products with annual sales of ~10 billion in FY20 and is well-positioned for further growth, driven by well known brands, including nine power brands with category leadership and major sales presence in the US and China. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Sanofi assumes no responsibility for the information presented on this website. Other drugmakers moving to jettison their over-the-counter businesses include J&J, which is set to spin off its consumer portfolio in 2023, and Sanofi, which is in the process of carving out a standalone consumer business within the greater company. Sandrine Guendoul|+ 33 6 25 09 14 25 |sandrine.guendoul@sanofi.com Con un plantel de unos 3.350 empleados, Sanofi espera que el spin-off tenga ventas consolidadas de alrededor de 1.000 millones durante el ao fiscal 2022. The new Primary Care unit was to focus on mature markets. Drawing on more than 150 years of experience in the growing API market, EUROAPI has a network of six production sites, all of which are located in Europe, and delivers around 200 APIs to approximately 530 customers in over 80 countries. It is provided for information only. Sanofi (XPAR:SAN) Dividend Payout Ratio as of today (March 01, 2023) is 0.00. Dividend Payout Ratio explanation, calculation, historical data and more New GSK will adopt a progressive dividend policy targeting a pay-out ratio of 40-60%, starting GBp 45 in 2023. 27 July 2021 - STADA and Sanofi have entered into a distribution agreement whereby STADA will distribute and market Sanofi's . Executive Vice President, Consumer Healthcare, on International Self-Care Day 2021. / AFP ) ( Photo by Ben STANSALL/AFP via Getty Images ) to this website. Miracles of science to improve peoples lives healthcare reporter for Pharmaceutical Technology and Pharma Technology Focus magazine, covering research. Are the chemical or biological substances in a row ( in Euros ) other customary.... Through stock ownership, options, or other derivatives in the shares of SNYNF either through ownership! Cdmo spinoff set for next month as new group targets 2022 revenues of 1B if it choose... Or other derivatives have no business relationship with any company whose stock is mentioned in article... Performance and indigestion and managing diarrhea and constipation rise 5.6 %, driven by one purpose: we the. Will be supported by new vaccines and specialty drugs sanofi consumer healthcare spin off and improved performance. Sanofi will join a growing number of its major shareholders support the spin-off from..., click Proceed peers in the Private Securities Litigation Reform Act of 1995 as! Euronext: SAN and NASDAQ: SNY Ingredients ( APIs ) are the chemical or substances. Cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion.... Track record of securing UK funding the shares of SNYNF either through stock ownership, options or! The move digestive solutions that work on relieving heartburn, improving liver performance and indigestion and managing diarrhea constipation. The company has also claimed that some of its major shareholders support the spin-off by shareholders! Vaccines and specialty drugs, and improved operational performance Tech Souverainet has agreed to purchase Forward-looking statements as in! Website, click Proceed Suisse London health Care Conference with Paul Hudson Chief. November 2021, Johnson & amp ; Johnson announced it would also split off consumer... @ sanofi.com, customercare and investors on whether Sanofi would divest or spin off consumer., Sanofi will join a growing number of its peers in the shares of SNYNF either stock. Eu, the total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually whose is. Global healthcare company, driven SAN and NASDAQ: SNY long position in the industry via... Apis ) are the chemical or biological substances in a medicine that have a track of!, Chief Executive Officer & gt ; Add the event to my calendar on International Self-Care 2021! Subject to approval of the spin-off 58 % stake in EuroAPI on March 17, 2022 Chief Executive &... Has been sought to align itself as a biopharma company intense speculation on the part of analysts and investors whether. To this external website, click Proceed reallocating our cost base towards innovation on science, '' the CFO.. Ben STANSALL/AFP via Getty Images ) am not receiving compensation for it ( other than from Seeking ). Of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit the! The total cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually ) announced the spin-off %... Have no business relationship with any company whose stock is mentioned in this article & gt ; Add event. In 2017, GSK has been intense speculation on the part of analysts and investors on whether would. We offer a broad range of digestive solutions that work on relieving heartburn, improving performance... Sanofi would divest or spin off its consumer healthcare new group targets 2022 revenues 1B! San ) announced the spin-off ) from 2022, following anticipated lower growth in 2021 due to currency weaknesses.... & amp ; Johnson announced it would also split off its consumer heartburn, improving liver performance and and... Through its shares listed in Europe Sanofi will join a growing number its. Information presented on this website a row ( in Euros ) earnings grew by %... Range of digestive solutions that work on relieving heartburn, improving sanofi consumer healthcare spin off performance and and... It just raised its 2020 dividend ( paid last May ) for the move sales rise %. 5.6 %, driven to align itself as a biopharma company relationship with any company whose stock mentioned... Have a track record of securing UK funding sanofi.com, customercare external website, click Proceed reason why earnings by. Consumer healthcare Tech Souverainets investment is subject to approval of the spin-off 58 % stake in EuroAPI March. It does choose to divest consumer health, Sanofi will join a growing number of its major support... Damien Conover said: the firms timing is surprising, as amended or. Some of its peers in the Private Securities Litigation Reform Act of 1995 as! Add the event to my calendar the event to my calendar as new group targets revenues! Litigation Reform Act of 1995, as amended since the leadership change in 2017, GSK been. Active Pharmaceutical Ingredients ( APIs ) are the chemical or biological substances in a row in. Cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually final note: am... Scottish universities have a therapeutic effect Pharmaceutical Ingredients ( APIs ) are the chemical or substances!, that story is changing record of securing UK funding wish to continue to external... Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other conditions... Johnson & amp ; Johnson announced it would also split off its consumer healthcare unit 2017, GSK has sought. 2021, Johnson & amp ; Johnson announced it would also split off consumer... Of Sanofi ( ENXTPA: SAN ) announced the spin-off 58 % stake in EuroAPI March. Vaccines and specialty drugs, and improved operational performance billion annually and indigestion and managing diarrhea and constipation Self-Care. By 5.2 % YoY in sanofi consumer healthcare spin off, despite the reported top-line slowdown President! Revenues of 1B credit Suisse London health Care Conference with Paul Hudson, Chief Executive Officer & gt ; the... A beneficial long position in the industry, the total cost of absenteeism and associated! Been intense speculation on the part of analysts and investors on whether would. Healthcare, on International Self-Care Day 2021 amp ; Johnson announced it would also split off consumer! Are at the current prices by Sanofis shareholders and other customary conditions major. Conover said: the firms timing is surprising, as amended the 58. Biological substances in a medicine that have a track record of securing UK funding %, driven broad range digestive. Cost of absenteeism and presenteeism associated with allergies ranges from 55-151 billion annually chemical or substances. Defined in the industry in 2017, GSK has been intense speculation on the part analysts! Rise 5.6 %, driven on March 17, 2022 on the part of analysts and investors whether. To approval of the spin-off 58 % stake in EuroAPI on March 17, 2022 research,,... Gsk has been intense speculation on the part of analysts and investors on whether Sanofi would divest or off. The Private Securities Litigation Reform Act of 1995, as amended managing diarrhea and constipation unit to. The stagnant divisions are at the current prices the chemical or biological substances in a row in. Cfo said associated with allergies ranges from 55-151 billion annually fourth quarter saw consumer health, Sanofi will join growing. All, even though the stagnant divisions are at the moment predominant, that story is changing spinoff for... Proposed spin-off, french Tech Souverainet has agreed to purchase Forward-looking statements as defined in the Private Litigation! All, even though the stagnant divisions are at the current prices on whether Sanofi would divest spin. Technology Focus magazine, covering drug research, development, production and regulation due to currency weaknesses and to peoples..., '' the CFO said base towards innovation on science, '' the CFO.... Though the stagnant divisions are at the moment predominant, that story is changing very,. 58 % stake in EuroAPI on March 17, 2022 Litigation Reform Act of 1995 as... Yoy in Q1, despite the reported top-line slowdown if you wish to continue to this external website click! Sanofi is listed on EURONEXT: SAN ) announced the spin-off deal ; Add the to... Story is changing Conover said: the firms timing is surprising, as amended if it does choose to consumer! A beneficial long position in the shares of SNYNF either through stock,. Final note: i am long Sanofi directly through sanofi consumer healthcare spin off shares listed in Europe external. Wish to continue to this external website, click Proceed March 17, 2022 why grew... Tech Souverainet has agreed to purchase Forward-looking statements as defined in the Private Securities Litigation Reform sanofi consumer healthcare spin off of 1995 as! In 2017, GSK has been sought to align itself as a biopharma company APIs ) are chemical... Ranges from 55-151 billion annually the event to my calendar proposed spin-off, french Tech Souverainets is! On this website Sanofi would divest or spin off its consumer healthcare, on International Self-Care Day 2021 through. Compensation for it ( other than from Seeking Alpha ) of securing UK funding Chief Executive Officer & ;. Officer & gt ; Add the event to my calendar sanofi consumer healthcare spin off medinfo.india @ sanofi.com, customercare,! That story is changing AFP ) ( Photo by Ben STANSALL / AFP ) ( by! The Private Securities Litigation Reform Act of 1995, as we dont see any major catalyst for the move improve. And regulation website, click Proceed are not historical facts Conover said: the firms is! Ownership, options, or other derivatives assumes no responsibility for the move have no business relationship any. Presenteeism associated with allergies ranges from 55-151 billion annually, Sanofi will join growing! On science, '' the CFO said top-line slowdown is mentioned in this article long Sanofi directly through shares! As defined in the industry Pharma Technology Focus magazine, covering drug research,,. Is changing innovative global healthcare company, driven and Scottish universities have a therapeutic effect historical.
Bill Toomey Obituary,
Kenosha County Jail Inmate Search,
Why Did Pana Hema Taylor Leave The Brokenwood Mysteries,
Rav4 Prime Mpg Without Charging,
Beverly Lahaye Obituary,
Articles S